The discussion focuses on emerging technologies and diagnostic tools for the early detection of metastatic colorectal cancer (mCRC). Ben George, MD, and John L. Marshall, MD, share insights into the challenges and prospects of early detection.

Dr George highlights the need for noninvasive methods for the early detection of colorectal cancer, emphasizing the importance of anatomic localization to guide treatment. Although various tests such as the fecal immunohistochemical test and circulating tumor DNA–based panels show promise, there is still a long way to go before widespread early detection through blood-based tests is achieved. The challenge lies in accurately identifying adenomas or cancer without a colonoscopy or imaging.

Dr Marshall adds that early detection remains a challenge in colorectal cancer. Noninvasive testing holds potential, but the technology is still in its infancy. He stresses the importance of anatomic localization to guide treatment effectively.

David Fenstermacher, PhD, highlights the need to understand the mechanisms of metastasis and escape mechanisms in cancer. This understanding can lead to the development of treatments that prevent metastasis or effectively target the escape mechanisms. He also stresses the significance of researching molecular subtypes in colorectal cancer and the importance of translational and clinical research to improve patient care.

Ryan Haumschild, PharmD, MS, MBA, acknowledges the existing gaps in colorectal cancer research. These gaps present opportunities for improving treatment and reducing disease progression. The discussion underscores the significance of enhancing screening mechanisms, addressing unknowns, and collecting data to advance research and patient care.

Dr Marshall also introduces the concept of digital pathology, a technology that utilizes digital imagery of glass slides to predict patient outcomes and treatment decisions based on eye-type analysis. Although these approaches are not yet widely available, they hold potential for revolutionizing screening efficiency in the next 2 to 5 years.

The panel agrees that the field of early detection and screening for mCRC is still evolving, but exciting times lie ahead with the potential for more efficient and effective screening strategies in the near future.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.